HC Wainwright Issues Positive Outlook for NRIX Earnings

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2025 EPS estimates for Nurix Therapeutics in a research note issued on Monday, July 14th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.68) per share for the quarter, up from their prior forecast of ($0.76). HC Wainwright has a "Buy" rating and a $34.00 price objective on the stock. The consensus estimate for Nurix Therapeutics' current full-year earnings is ($2.99) per share. HC Wainwright also issued estimates for Nurix Therapeutics' Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($0.97) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.73) EPS.

A number of other equities analysts have also recently commented on NRIX. Oppenheimer set a $30.00 target price on Nurix Therapeutics and gave the company an "outperform" rating in a report on Thursday, July 10th. Wells Fargo & Company cut their price objective on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 9th. Morgan Stanley set a $16.00 target price on Nurix Therapeutics and gave the company an "equal weight" rating in a report on Tuesday. Stephens restated an "overweight" rating and set a $30.00 price target on shares of Nurix Therapeutics in a report on Thursday, July 10th. Finally, Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.31.

Nurix Therapeutics Stock Performance

Shares of NRIX traded down $0.25 during midday trading on Wednesday, hitting $11.85. 230,913 shares of the stock were exchanged, compared to its average volume of 846,070. Nurix Therapeutics has a 52-week low of $8.18 and a 52-week high of $29.56. The stock has a fifty day simple moving average of $11.43 and a 200 day simple moving average of $13.65. The firm has a market cap of $905.55 million, a P/E ratio of -4.57 and a beta of 2.15.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.79) by $0.27. The firm had revenue of $44,056 billion during the quarter, compared to analysts' expectations of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%.

Insider Buying and Selling at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the sale, the insider directly owned 61,516 shares of the company's stock, valued at approximately $707,434. This represents a 5.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Houte Hans Van sold 6,198 shares of the firm's stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.33, for a total value of $70,223.34. Following the transaction, the chief financial officer directly owned 33,724 shares in the company, valued at approximately $382,092.92. This represents a 15.53% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,013 shares of company stock valued at $137,096. 7.40% of the stock is owned by insiders.

Institutional Trading of Nurix Therapeutics

A number of hedge funds have recently added to or reduced their stakes in NRIX. US Bancorp DE boosted its holdings in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after purchasing an additional 842 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Nurix Therapeutics in the fourth quarter worth $28,000. Aquatic Capital Management LLC acquired a new position in shares of Nurix Therapeutics in the fourth quarter worth $87,000. Summit Investment Advisors Inc. boosted its stake in shares of Nurix Therapeutics by 13.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after purchasing an additional 877 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Nurix Therapeutics during the fourth quarter worth about $164,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.